Antibody drugs targeting SARS-CoV-2: Time for a rethink?

被引：3
作者：
Liang, Likeng [1 ]
Wang, Bo [1 ]
Zhang, Qing [2 ]
Zhang, Shiwu [3 ]
Zhang, Sihe [1 ]
机构：
[1] Nankai Univ, Sch Med, Dept Cell Biol, 94 Weijin Rd, Tianjin 300071, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Lab Med, Tianjin 300060, Peoples R China
[3] Nankai Univ, Tianjin Union Med Ctr, Dept Pathol, Tianjin 300121, Peoples R China
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2024年 / 176卷
关键词：
SARS-CoV-2; Mutations; Therapeutic antibody; Immune evasion; Design strategy; SARS CORONAVIRUS; SEVERE COVID-19; SPIKE PROTEIN; BINDING; MULTICENTER; INFECTION; VARIANTS; PHASE-2;
D O I：
10.1016/j.biopha.2024.116900
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) heavily burdens human health. Multiple neutralizing antibodies (nAbs) have been issued for emergency use or tested for treating infected patients in the clinic. However, SARS-CoV-2 variants of concern (VOC) carrying mutations reduce the effectiveness of nAbs by preventing neutralization. Uncoding the mutation profile and immune evasion mechanism of SARS-CoV-2 can improve the outcome of Ab-mediated therapies. In this review, we first outline the development status of anti-SARS-CoV-2 Ab drugs and provide an overview of SARS-CoV-2 variants and their prevalence. We next focus on the failure causes of anti-SARS-CoV-2 Ab drugs and rethink the design strategy for developing new Ab drugs against COVID-19. This review provides updated information for the development of therapeutic Ab drugs against SARS-CoV-2 variants.
引用
收藏
页数：18
相关论文
共 194 条
  • [1] What to Know About EG.5, the Latest SARS-CoV-2 "Variant of Interest"
    Abbasi, Jennifer
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (10): : 900 - 901
  • [2] Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
    Abulsoud, Ahmed I.
    El-Husseiny, Hussein M.
    El-Husseiny, Ahmed A.
    El-Mahdy, Hesham A.
    Ismail, Ahmed
    Elkhawaga, Samy Y.
    Khidr, Emad Gamil
    Fathi, Doaa
    Mady, Eman A.
    Najda, Agnieszka
    Algahtani, Mohammad
    Theyab, Abdulrahman
    Alsharif, Khalaf F.
    Albrakati, Ashraf
    Bayram, Roula
    Abdel-Daim, Mohamed M.
    Doghish, Ahmed S.
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2023, 157
  • [3] Neutralization, effector function and immune imprinting of Omicron variants
    Addetia, Amin
    Piccoli, Luca
    Case, James Brett
    Park, Young-Jun
    Beltramello, Martina
    Guarino, Barbara
    Dang, Ha
    de Melo, Guilherme Dias
    Pinto, Dora
    Sprouse, Kaitlin
    Scheaffer, Suzanne M.
    Bassi, Jessica
    Silacci-Fregni, Chiara
    Muoio, Francesco
    Dini, Marco
    Vincenzetti, Lucia
    Acosta, Rima
    Johnson, Daisy
    Subramanian, Sambhavi
    Saliba, Christian
    Giurdanella, Martina
    Lombardo, Gloria
    Leoni, Giada
    Culap, Katja
    Mcalister, Carley
    Rajesh, Anushka
    Dellota, Exequiel
    Zhou, Jiayi
    Farhat, Nisar
    Bohan, Dana
    Noack, Julia
    Chen, Alex
    Lempp, Florian A.
    Quispe, Joel
    Kergoat, Lauriane
    Larrous, Florence
    Cameroni, Elisabetta
    Whitener, Bradley
    Giannini, Olivier
    Cippa, Pietro
    Ceschi, Alessandro
    Ferrari, Paolo
    Franzetti-Pellanda, Alessandra
    Biggiogero, Maira
    Garzoni, Christian
    Zappi, Stephanie
    Bernasconi, Luca
    Kim, Min Jeong
    Rosen, Laura E.
    Schnell, Gretja
    [J]. NATURE, 2023, 621 (7979) : 592 - +
  • [4] Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
    Alenquer, Marta
    Ferreira, Filipe
    Lousa, Diana
    Valerio, Mariana
    Medina-Lopes, Monica
    Bergman, Marie-Louise
    Goncalves, Juliana
    Demengeot, Jocelyne
    Leite, Ricardo B.
    Lilue, Jingtao
    Ning, Zemin
    Penha-Goncalves, Carlos
    Soares, Helena
    Soares, Claudio M.
    Amorim, Maria Joao
    [J]. PLOS PATHOGENS, 2021, 17 (08)
  • [5] Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies
    Almagro, Juan C.
    Mellado-Sanchez, Gabriela
    Pedraza-Escalona, Martha
    Perez-Tapia, Sonia M.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (17)
  • [6] Annane Djillali, 2023, Lancet Respir Med, V11, P1051, DOI 10.1016/S2213-2600(23)00082-6
  • [7] Emerging roles of SARS-CoV-2 Spike-ACE2 in immune evasion and pathogenesis
    Baldari, Cosima T.
    Onnis, Anna
    Andreano, Emanuele
    Del Giudice, Giuseppe
    Rappuoli, Rino
    [J]. TRENDS IN IMMUNOLOGY, 2023, 44 (06) : 424 - 434
  • [8] SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
    Barnes, Christopher O.
    Jette, Claudia A.
    Abernathy, Morgan E.
    Dam, Kim-Marie A.
    Esswein, Shannon R.
    Gristick, Harry B.
    Malyutin, Andrey G.
    Sharaf, Naima G.
    Huey-Tubman, Kathryn E.
    Lee, Yu E.
    Robbiani, Davide F.
    Nussenzweig, Michel C.
    West, Anthony P., Jr.
    Bjorkman, Pamela J.
    [J]. NATURE, 2020, 588 (7839) : 682 - +
  • [9] Barnes CO, 2020, CELL, V182, P828, DOI [10.1101/2020.05.28.121533, 10.1016/j.cell.2020.06.025]
  • [10] Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
    Baum, Alina
    Fulton, Benjamin O.
    Wloga, Elzbieta
    Copin, Richard
    Pascal, Kristen E.
    Russo, Vincenzo
    Giordano, Stephanie
    Lanza, Kathryn
    Negron, Nicole
    Ni, Min
    Wei, Yi
    Atwal, Gurinder S.
    Murphy, Andrew J.
    Stahl, Neil
    Yancopoulos, George D.
    Kyratsous, Christos A.
    [J]. SCIENCE, 2020, 369 (6506) : 1014 - +
12345678910